Metastatic renal cell carcinoma (RCC) often develops resistance to first-line targeted therapy such as sunitinib. G-Protein-coupled estrogen receptor 1 (GPER1) agonist G-1 was recently reported to regulate RCC physiology but the role of G-1 in RCC tumorigenesis and sunitinib resistance remains largely unknown.

中文翻译：

---

G-蛋白偶联雌激素受体 1 激动剂 G-1 扰乱肾细胞癌中舒尼替尼耐药相关的磷酸化蛋白质组学特征。

转移性肾细胞癌 (RCC) 通常会对舒尼替尼等一线靶向治疗产生耐药性。最近有报道称 G-蛋白偶联雌激素受体 1 (GPER1) 激动剂 G-1 可调节 RCC 生理机能，但 G-1 在 RCC 肿瘤发生和舒尼替尼耐药中的作用仍然未知。